Cytomx therapeutics, inc. (CTMX)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Sep'14
Revenues

77,597

57,489

60,681

62,478

74,803

59,502

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Revenues

-

-

-

-

-

-

-

-

-

-

-

-

22,238

-

8,669

7,311

6,329

5,941

0

0

0

-

Revenues from related parties

-

-

-

-

-

-

-

-

-

-

2,006

2,149

2,235

2,198

2,090

1,933

1,864

1,771

0

0

0

-

Total revenues

-

-

-

-

-

-

-

-

-

-

50,821

30,131

24,473

15,043

10,759

9,244

8,193

7,712

7,639

0

0

0

Operating expenses:
Research and development

138,057

131,619

123,484

123,066

117,784

103,866

96,265

97,636

100,159

92,277

86,920

71,337

55,966

54,755

48,910

44,730

37,058

28,357

22,770

0

0

0

General and administrative

36,663

36,765

36,523

36,197

35,828

33,510

32,151

30,263

27,270

25,605

23,143

21,927

20,525

19,874

18,729

17,747

15,652

12,558

10,012

0

0

0

Total operating expenses

174,720

168,384

160,007

159,263

153,612

137,376

128,416

127,899

127,429

117,882

110,063

93,264

76,491

74,629

67,639

62,477

52,710

40,915

32,782

0

0

0

Loss from operations

-97,123

-110,895

-99,326

-96,785

-78,809

-77,874

-53,311

-41,159

-53,275

-46,259

-59,242

-63,133

-52,018

-59,586

-56,880

-53,233

-44,517

-33,203

-25,143

0

0

0

Interest income

6,944

8,365

9,361

9,583

8,762

7,641

6,409

4,996

3,813

2,674

1,240

644

482

736

1,336

1,533

1,667

1,315

876

0

0

0

Interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,855

1,732

1,473

0

0

0

Other income (expense)

-62

-135

-145

-138

11

-68

24

-52

-287

-27

-124

-32

32

-69

-72

-404

-474

-1,744

-1,728

0

0

0

Loss before income taxes

-90,241

-102,665

-90,110

-87,340

-70,036

-70,301

-46,878

-36,215

-49,749

-43,612

-57,773

-62,168

-51,151

-58,919

-56,345

-53,551

-45,179

-35,364

-27,468

0

0

0

Benefit from income taxes

-14,321

-427

8,899

11,399

13,199

14,303

4,879

2,360

586

-513

-20

0

-23

-19

10

14

0

-

0

0

-

-

Net income (loss)

-75,909

-102,238

-99,016

-98,748

-83,235

-84,604

-51,750

-38,566

-50,335

-43,099

-57,753

-62,168

-51,128

-58,900

-56,354

-53,562

-45,192

-35,374

-27,476

0

0

0

Net income (loss) per share
Basic

0.27

-

-

-

-0.31

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Diluted

0.26

-

-

-

-0.31

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Shares used to compute net income (loss) per share
Basic

45,723

-

-

-

45,122

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Diluted

47,044

-

-

-

45,122

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accretion to redemption value and cumulative dividends on preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

6,705

7,316

0

0

0

Net loss attributable to common stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-42,079

-34,792

0

0

0

Net loss per share, basic and diluted

-

-

-0.52

-0.64

-

-0.75

-0.53

-0.35

-0.40

0.04

-0.28

-0.69

-0.23

-0.40

-0.40

-0.39

-0.44

24.59

-14.26

-7.56

-7.67

-4.86

Shares used to compute net loss per share, basic and diluted

-

-

45,418

45,340

-

45,131

43,917

38,961

38,647

38,400

36,947

36,780

36,538

36,437

36,324

36,113

36,063

31,343

1,039

1,001

996

979

Other comprehensive income:
Unrealized gain on short-term investments, net of tax

263

139

307

376

290

1

-147

-68

-128

-67

-69

-190

-130

49

16

81

40

-76

0

0

0

-

Impact of adoption of new accounting pronouncement

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total other comprehensive (loss) / income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

16

81

40

-

0

0

0

-

Comprehensive income (loss)

-75,646

-102,088

-98,698

-98,361

-82,934

-84,603

-51,897

-38,634

-50,463

-43,166

-57,822

-62,358

-51,258

-58,851

-56,338

-53,481

-45,152

-35,450

-27,484

0

0

0